Abstract
The metabolic syndrome—otherwise called syndrome X, insulin resistance syndrome, Reaven syndrome, and “the deadly quartet”—is the name given to the aggregate of clinical conditions comprising central and abdominal obesity, systemic hypertension, insulin resistance (or type 2 diabetes mellitus), and atherogenic dyslipidemia. It is a prothrombotic and proinflammatory state characterized by increased inflammatory cytokine activity. In addition to inflammatory dermatoses such as psoriasis, lichen planus, and hidradenitis suppurativa, metabolic syndrome is also commonly associated with accelerated atherosclerotic cardiovascular disease, hyperuricemia/gout, chronic kidney disease, and obstructive sleep apnea. Current therapeutic options for metabolic syndrome are limited to individual treatments for hypertension, hyperglycemia, and hypertriglyceridemia, as well as dietary control measures and regular exercise.
Original language | English |
---|---|
Pages (from-to) | 14-20 |
Number of pages | 7 |
Journal | Clinics in Dermatology |
Volume | 36 |
Issue number | 1 |
Early online date | 11 Dec 2017 |
DOIs | |
Publication status | Published - 01 Jan 2018 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2017
ASJC Scopus subject areas
- Dermatology